Advisory Research Inc Ascendis Pharma A/S Transaction History

Advisory Research Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 12, 2021	SELL	$124.92 - $173.33 $1.91 Million - $2.65 Million	-15,276 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$151.2 - $182.76 $520,732 - $629,425	3,444 Added 29.11%	15,276 $2.55 Million
Q3 2020 Nov 12, 2020	SELL	$134.29 - $154.32 $353,854 - $406,633	-2,635 Reduced 18.21%	11,832 $1.83 Million
Q2 2020 Aug 13, 2020	BUY	$110.87 - $156.01 $133,487 - $187,836	1,204 Added 9.08%	14,467 $2.14 Million
Q1 2020 May 12, 2020	SELL	$97.01 - $145.11 $263,188 - $393,683	-2,713 Reduced 16.98%	13,263 $1.49 Million
Q4 2019 Feb 11, 2020	BUY	$91.45 - $139.12 $202,836 - $308,568	2,218 Added 16.12%	15,976 $2.22 Million
Q3 2019 Nov 12, 2019	SELL	$95.8 - $118.9 $449,110 - $557,403	-4,688 Reduced 25.41%	13,758 $1.33 Million
Q2 2019 Aug 14, 2019	BUY	$107.11 - $132.09 $232,642 - $286,899	2,172 Added 13.35%	18,446 $2.12 Million
Q1 2019 May 15, 2019	SELL	$62.15 - $129.99 $60,347 - $126,220	-971 Reduced 5.63%	16,274 $1.92 Million
Q4 2018 Feb 13, 2019	BUY	$55.16 - $69.67 $298,525 - $377,054	5,412 Added 45.74%	17,245 $1.08 Million
Q3 2018 Nov 13, 2018	BUY	$63.77 - $76.28 $754,590 - $902,621	11,833 New	11,833 $838,000

235

59.5M

80.3K

216K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $8.7B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.